A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal

Abstract

These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation.

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1

“… 6 , 8 , 9 , 12 However, this number was reported as low as 3-4 in most of the real-world practice studies. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 In addition, 12-13 visits are necessary in an ideal PRN treatment follow-up protocol. 6 , 7 The mean visit number was 6.9 in our study.…”

“…In several previous real-world studies the mean visit number was found to be between 6 and 12. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 …”

“…In most real-world studies, visit and injection numbers were determined to be very far from the ideal. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 This may be secondary to heavy patient load, visit and injection scheduling problems, and patient compliance. Therefore, we might suppose that the PRN treatment regimen may not be suitable for the treatment of nAMD in daily practice according to our results and most of the other studies results.…”

“… 8 However, most of the subsequently published real-world practice studies revealed that it was not possible to obey the strict follow-up and retreatment criteria of randomized controlled trials in daily practice. 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 Most of these studies showed that the PRN regimen resulted in less frequent patient monitoring and injections. Several single-center and multicenter national studies were conducted to evaluate this phenomenon.…”

“…Several single-center and multicenter national studies were conducted to evaluate this phenomenon. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 Therefore, we conducted this multicenter study to assess the real-world outcomes of intravitreal anti-VEGF treatment in nAMD patients in 9 tertiary centers, all of which are located in or near İstanbul, the most populated city in Turkey, and we believe may reflect the general trends of treatment regimens in Turkey.…”